CSIMarket Company Name, Ticker, Competitors, else..
 
Cybin Inc   (NYSEAMER: CYBN)
 

Cybin Inc's Suppliers Performance

CYBN's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
CYBN Costs vs Sales of Suppliers Growth

• More on CYBN Suppliers






Cybin Inc's Comment on Supply Chain


The Company sources raw materials for its development operations from licensed third-party suppliers in Canada, the United States, the UK, and Europe. These materials are generally expected to be readily available and sufficient for development quantities or custom manufacturing. Prices for research quantities of novel tryptamine compounds are higher than commercial supply prices at larger scales, with an expectation of price reductions over time. Development and production of proprietary novel compounds are conducted under confidential contractual agreements. The Company has conducted due diligence on each supplier, including reviewing licenses and regulatory compliance. Capital allocation and project timing depend on the success and results of each phase, making exact costs and timelines difficult to predict. The Company adheres to pharmaceutical industry practices regarding disclosure to protect proprietary technology and intellectual property rights.

Cybin Inc's Comment on Supply Chain


The Company sources raw materials for its development operations from licensed third-party suppliers in Canada, the United States, the UK, and Europe. These materials are generally expected to be readily available and sufficient for development quantities or custom manufacturing. Prices for research quantities of novel tryptamine compounds are higher than commercial supply prices at larger scales, with an expectation of price reductions over time. Development and production of proprietary novel compounds are conducted under confidential contractual agreements. The Company has conducted due diligence on each supplier, including reviewing licenses and regulatory compliance. Capital allocation and project timing depend on the success and results of each phase, making exact costs and timelines difficult to predict. The Company adheres to pharmaceutical industry practices regarding disclosure to protect proprietary technology and intellectual property rights.







CYBN's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Cybin Inc 167.44 159.15 -86.66 30
SUBTOTAL 0.00 0.00 0.00 -


Sources: Cybin Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cybin Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.